Cerus Corporation (NASDAQ: CERS) is a Healthcare company (Medical - Devices) with a market capitalization of $384M. The Maz Rating grades it against the other companies in its sector.
Cerus Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $1.90, Cerus Corporation trades at 1.7x sales and 5.0x book value. Over the last twelve months it generated about $231M of revenue and a net loss of $8M. It runs a gross margin of 51.8%, an operating margin of -3.9% and a net margin of -3.2%. It shows return on equity of -10.5%, return on invested capital of -5.6% and a free cash flow yield of 0.1%. On the balance sheet: a debt-to-equity ratio of 0.99 and a current ratio of 1.96. Over the past 52 weeks the share price ranged from $1.47 to $3.47, with a beta of 1.85.
Cerus Corporation does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 8 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Cerus Corporation (CERS) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 13.0% / 30% · (Cash+Inv) / Mkt Cap (36m) 11.7% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 13.0% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 11.7% / 33% · Receivables / Mkt Cap (36m) 6.28% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 13.0% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 11.7% / 33.33% · Receivables / Mkt Cap (24m) 6.28% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 34.7% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 32.4% / 33.33% · Receivables / Avg Assets (4Q) 14.2% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 30.9% / 33.33% · (Cash+ST Inv) / Total Assets 27.9% / 33.33% · (Cash+Recv) / Total Assets 42.8% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Cerus Corporation (CERS) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Cerus Corporation is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Cerus Corporation reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.